CA-YUBICO
6.5.2024 15:01:34 CEST | Business Wire | Press release
Today Yubico (NASDAQ: YUBICO), the leading provider of hardware authentication security keys, announced the upcoming release of YubiKey 5.7 firmware for the YubiKey 5 Series, Security Key Series and Security Key Series - Enterprise Edition. With a focus on enterprise needs, these updates reinforce Yubico’s commitment to providing secure, simple, and scalable authentication solutions. Security keys with firmware 5.7 will be available to purchase in late May 2024, offering enhanced features such as improved PIN complexity, enterprise attestation, and expanded passkey credentials storage. These updates empower organizations to adopt passwordless-first, modern authentication, fostering phishing-resistant users worldwide.
As part of Yubico’s goal of helping enterprises raise the bar for security with greater flexibility, the company also announced the availability of Yubico Authenticator 7 which will support the upcoming YubiKey 5.7 features.
“Organizations are continuing to face a surge in the variety and complexity of cyber threats at historical rates, often fueled by compromised employee login credentials, frequently resulting from attacks such as phishing. This trend is exacerbated by the rise in use of Artificial Intelligence (AI),” said Jeff Wallace, senior vice president of product at Yubico. “We’re excited to continue offering best-in-class solutions that protect organizations and accelerate their transition to passwordless with the latest enterprise-focused updates to the YubiKey. We’re confident that organizations are now better equipped than ever to enforce compliance requirements and elevate their security posture throughout their organization.”
YubiKey 5.7: Accelerating enterprises to passwordless
To help organizations tackle this challenge, Yubico’s key updates and enhancements to the YubiKey 5 Series and Security Key Series* include:
-
Enhanced PIN complexity across all YubiKey applications
- Block simple patterns and common PINs at the hardware level to enable compliance with upcoming NIST requirements and corporate mandates. This includes FIDO2, PIV, and OpenPGP.
-
Enterprise attestation
- Allow organizations to enforce the usage of YubiKeys that they purchased via custom programmed keys with enterprise attestation. Working in conjunction with identity providers, this capability can also facilitate the retrieval of unique identifiers during FIDO2 registration to streamline asset tracking and account recovery.
-
FIDO2 enhancements
- Empower organizations to enforce compliance requirements and elevate security measures surrounding PIN usage. YubiKey 5.7 implements FIDO Client-to-Authenticator Protocol (CTAP) 2.1, embracing the latest FIDO2 protocol features such as Force PIN Change and Minimum PIN Length.
-
Expanded passkey and passwordless storage
- Provide ample storage space to meet authentication needs while maintaining strong security standards. More storage for FIDO2 discoverable credentials (passkeys) and OATH one-time passwords will now accommodate up to 100 passkeys, 24 PIV certificates, 64 OATH seeds, and 2 OTP seeds at once for a total of 190 credentials.
-
Expansion and enhancement of public key algorithms for PIV applications
- Align with DoD memo requirements and offer advanced key management functions, enhancing flexibility for organizations through support of larger RSA keys (RSA-3072 and RSA-4096), as well as Ed25519 and X25519 key types.
-
Migration to Yubico’s own cryptographic library
- Yubico has developed a library in-house that performs the underlying cryptographic operations (decryption, signing, etc.) for RSA and ECC.
“The new features within 5.7 allow enterprises to streamline critical processes such as asset tracking and account recovery, while also enhancing flexibility,” said Wallace. “These updates empower enterprises with the latest authentication advancements and tools to build specific strategies for creating phishing-resistant users and mitigating phishing threats for employees, external identities, and customers.”
Capabilities in the new 5.7 YubiKeys also align with recent U.S. Government memo requirements on adopting phishing-resistant MFA and offer advanced key management functions. Compliance with upcoming NIST requirements and corporate mandates is also supported by enforcing the blocking of simple patterns and common PINs at the hardware level.
*Note: Smart Card/PIV capabilities, OATH and OTP credentials are not available on any Security Key Series thus these updates are not applicable. Enterprise attestation is available on the YubiKey 5 Series and Security Key Series - Enterprise Edition. See here for more details.
Yubico Authenticator 7: Hardware-backed authenticator app across desktop and mobile
Aligned with the 5.7 firmware release, significant updates within Yubico Authenticator 7 launched today in support of managing these new features. This new version enables use of the new public key algorithms for PIV, bringing more advanced management options and streamlines the interface for a better user experience when handling many credentials. Additionally, it adds localization with official support for French and Japanese, with additional community-provided translations. The app is now available for all major desktop platforms, as well as for Android. Enhanced features for iOS will be coming in the next version of the iOS application. It's the perfect companion to the new YubiKey 5.7, with its expanded credential storage.
The Yubico Authenticator delivers strong security by enabling users to store credentials on a YubiKey instead of a mobile phone, thereby significantly removing risks posed by remote attackers targeting software-based authenticator apps. By incorporating hardware-backed strong two-factor authentication in the YubiKey, credentials stays safe and the bar for security is raised while delivering the convenience of an authenticator app.
For more information on today’s innovation announcements from Yubico, visit here. To get the Yubico Authenticator 7 app, visit here.
About Yubico
Yubico (Nasdaq First North Growth Market Stockholm: YUBICO), the inventor of the YubiKey, offers the gold standard for phishing-resistant multi-factor authentication (MFA), stopping account takeovers in their tracks and making secure login easy and available for everyone. Since the company was founded in 2007, it has been a leader in setting global standards for secure access to computers, mobile devices, servers, browsers, and internet accounts. Yubico is a creator and core contributor to the FIDO2, WebAuthn, and FIDO Universal 2nd Factor (U2F) open authentication standards, and is a pioneer in delivering modern, hardware-based passkey authentication security at scale to customers in over 160 countries.
Yubico’s solutions enable passwordless logins using the most secure form of passkey technology. YubiKeys work out-of-the-box across hundreds of consumer and enterprise applications and services, delivering strong security with a fast and easy experience.
As part of its mission to make the internet more secure for everyone, Yubico donates YubiKeys to organizations helping at-risk individuals through the philanthropic initiative, Secure it Forward. The company is headquartered in Stockholm and Santa Clara, CA. For more information on Yubico, visit us at www.yubico.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240506185894/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
